Johnson & Johnson Lyell Immunopharma, Inc. Transaction History
Johnson & Johnson
- $293 Million
- Q4 2024
A detailed history of Johnson & Johnson transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Johnson & Johnson holds 823,317 shares of LYEL stock, worth $576,321. This represents 0.18% of its overall portfolio holdings.
Number of Shares
823,317Holding current value
$576,321% of portfolio
0.18%Shares
1 transactions
Others Institutions Holding LYEL
# of Institutions
108Shares Held
171MCall Options Held
7.7KPut Options Held
15.3K-
Mwg Management Ltd. Washington, DC20.2MShares$14.1 Million17.35% of portfolio
-
Orland Properties LTD Washington, DC15.1MShares$10.6 Million14.08% of portfolio
-
Apoletto LTD Washington, DC15.1MShares$10.6 Million42.56% of portfolio
-
Black Rock Inc. New York, NY13.5MShares$9.45 Million0.0% of portfolio
-
Decheng Capital LLC Menlo Park, CA11.9MShares$8.34 Million1.63% of portfolio
About Lyell Immunopharma, Inc.
- Ticker LYEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 247,824,992
- Market Cap $173M
- Description
- Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...